2022 - Research.com Immunology in China Leader Award
His scientific interests lie mostly in Virology, Coronavirus, Antibody, Gp41 and Peptide sequence. Shibo Jiang interconnects Epitope, Middle East respiratory syndrome coronavirus and Immunogenicity in the investigation of issues within Virology. His Coronavirus research includes themes of Nucleic acid amplification technique, Pneumonia, Receptor, Middle East respiratory syndrome and 2019-20 coronavirus outbreak.
In his work, Binding domain is strongly intertwined with Recombinant DNA, which is a subfield of Antibody. His study in Gp41 is interdisciplinary in nature, drawing from both Viral envelope, Heptad repeat, Lipid bilayer fusion, Biochemistry and Viral entry. His Peptide sequence study integrates concerns from other disciplines, such as Plasma protein binding, Binding site, Viral protein and Peptide.
His primary scientific interests are in Virology, Gp41, Antibody, Virus and Coronavirus. His Virology study also includes fields such as
His Antibody research integrates issues from Molecular biology and Antigen. His research in Virus tackles topics such as Sexual transmission which are related to areas like Entry inhibitor. His Coronavirus research incorporates elements of Outbreak, 2019-20 coronavirus outbreak, Protein subunit and Severe acute respiratory syndrome coronavirus 2.
The scientist’s investigation covers issues in Virology, Antibody, Severe acute respiratory syndrome coronavirus 2, Coronavirus and Virus. His research in Virology intersects with topics in Spike Protein, Monoclonal antibody and Peptide. The various areas that he examines in his Peptide study include Middle East respiratory syndrome coronavirus, Heptad repeat, Potency, Inhibitory postsynaptic potential and Enfuvirtide.
His studies deal with areas such as Gene, Immune system and Antigen as well as Antibody. As a part of the same scientific study, Shibo Jiang usually deals with the Severe acute respiratory syndrome coronavirus 2, concentrating on Protein subunit and frequently concerns with Plasma membrane fusion. His Coronavirus research focuses on Peptide sequence and how it relates to Plasma protein binding.
His primary areas of study are Virology, Severe acute respiratory syndrome coronavirus 2, Coronavirus, 2019-20 coronavirus outbreak and Antibody. His research in Virology is mostly focused on Lipid bilayer fusion. He combines subjects such as Middle East respiratory syndrome coronavirus, Intensive care medicine, Severe acute respiratory syndrome coronavirus, Pandemic and Monoclonal antibody with his study of Severe acute respiratory syndrome coronavirus 2.
His Coronavirus study combines topics from a wide range of disciplines, such as Nucleic acid amplification technique, Virus, Betacoronavirus and Pneumonia. His Antibody research is multidisciplinary, incorporating elements of In vivo and Binding site. His Binding site research is multidisciplinary, incorporating perspectives in HEK 293 cells and Receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Lanying Du;Yuxian He;Yusen Zhou;Shuwen Liu.
Nature Reviews Microbiology (2009)
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
Xiaolong Tian;Cheng Li;Ailing Huang;Shuai Xia.
Emerging microbes & infections (2020)
Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways.
Yanqing Ding;Li He;Qingling Zhang;Zhongxi Huang.
The Journal of Pathology (2004)
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Wanbo Tai;Lei He;Xiujuan Zhang;Jing Pu;Jing Pu.
Cellular & Molecular Immunology (2020)
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
Shuai Xia;Meiqin Liu;Chao Wang;Wei Xu.
Cell Research (2020)
HIV-1 inhibition by a peptide
Shibo Jiang;Kang Lin;N. Strick;A. R. Neurath.
Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.
Shuwen Liu;Gengfu Xiao;Yibang Chen;Yuxian He.
The Lancet (2004)
Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications
Wu F;Wang A;Liu M;Wang Q.
Social Science Research Network (2020)
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
Shibo Jiang;Shibo Jiang;Christopher Hillyer;Lanying Du.
Trends in Immunology (2020)
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
Lu Lu;Qi. Liu;Yun Zhu;Kwok-Hung Chan.
Nature Communications (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: